Correspondence 0001493152-26-004989 from Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc.
Date: Feb. 3, 2026 · CIK: 0000748592 · Accession: 0001493152-26-004989
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293150
Letter
Ernexa Therapeutics Inc.
Cambridge Street, Suite 18A
Cambridge, MA 02141
February 3, 2026
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
RE: Ernexa Therapeutics Inc.
Registration Statement on Form S-1
File No. 333-293150
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Requested Date: February 4, 2026
Requested Time: 4:30 pm, Eastern Time
Ladies and Gentlemen:
Ernexa Therapeutics Inc. (the "Company") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-293150), be accelerated pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it is declared and becomes effective at 4:30 pm Eastern Time on February 4, 2026, or as soon thereafter as possible.
Please contact our counsel, Lawrence Metelitsa of Lucosky Brookman LLP at (732) 395-4405 with any questions you may have regarding this request. In addition, the Company requests that you kindly notify Mr. Metelitsa by telephone when this request for acceleration has been granted.
Sincerely
yours,
ERNEXA
THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm Ernexa Therapeutics Inc. 1035 Cambridge Street, Suite 18A Cambridge, MA 02141 February 3, 2026 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Ernexa Therapeutics Inc. Registration Statement on Form S-1 File No. 333-293150 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: February 4, 2026 Requested Time: 4:30 pm, Eastern Time Ladies and Gentlemen: Ernexa Therapeutics Inc. (the "Company") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-293150), be accelerated pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it is declared and becomes effective at 4:30 pm Eastern Time on February 4, 2026, or as soon thereafter as possible. Please contact our counsel, Lawrence Metelitsa of Lucosky Brookman LLP at (732) 395-4405 with any questions you may have regarding this request. In addition, the Company requests that you kindly notify Mr. Metelitsa by telephone when this request for acceleration has been granted. Sincerely yours, ERNEXA THERAPEUTICS INC. /s/ Sanjeev Luther Sanjeev Luther President, Chief Executive Officer and Director